Full-Time

Principal Software Developer

Updated on 8/1/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Software Engineering (1)
Required Skills
LLM
Agile
Python
ERP
Data Science
Inventory Management
FDA Regulations
SQL
Machine Learning
Java
C#
REST APIs
Data Analysis

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A Bachelor's or Master's degree in Engineering, Information Technology, or a related field, with 12–18 years of experience.
  • A degree in Computer Science, Information Systems, Engineering, or Life Sciences.
  • Extensive experience designing, configuring, and coding software, including custom development and commercial software packages using application programming interfaces, within an Agile environment and contributing to ceremonies.
  • Experience with integration standards including Web Services, SOAP, and REST.
  • Experience with object-oriented design and development and semantic web standards.
  • Experience with development languages such as Java, Python, and Pipeline Pilot; C# is a plus.
  • Ability to learn new software, troubleshoot, and apply critical-thinking techniques to improvements.
  • Strong database management experience with SQL relational database management systems and SPARQL; Big Data integration and analytics experience is a plus.
  • Experience integrating solutions with enterprise resource planning and manufacturing execution system platforms is a plus.
  • Understanding of business, manufacturing, and laboratory systems common in the pharmaceutical industry and the integration of these systems through applicable standards.
  • Understanding of computer system validation and the software development life cycle in biotech manufacturing and laboratory areas.
  • Excellent verbal, written, and interpersonal communication skills, including the ability to set context and present sophisticated subjects to senior management clearly and concisely.
  • Experience building productive working relationships with business clients.
  • Strong leadership and project management skills.
  • Proven leadership skills with the ability to lead large matrixed teams and experience leading and developing technology professionals while building a culture of innovation and continuous improvement.
  • Experience implementing a strategic roadmap and driving transformation initiatives using Scaled Agile methodology.
  • Strong collaboration and communication skills with cross-functional teams, business collaborators, and executives to align platform initiatives with business outcomes, manage expectations, and ensure successful project delivery.
  • Excellent leadership and team management skills.
  • Strong transformation and change management experience.
  • Ability to work effectively with global, virtual teams.
  • Excellent analytical and troubleshooting skills.
  • Ability to manage multiple priorities successfully.
  • Strong presentation and public speaking skills.
  • Strong verbal and written communication skills.
  • High degree of initiative and self-motivation.
Responsibilities
  • Serve as a technical leader across multiple teams.
  • Coach mid-level and senior software development engineers.
  • Drive architectural decisions across multiple projects.
  • Maintain technical excellence and scalability in products.
  • Design, develop, and implement Information Systems solutions for end-to-end digitization of lab experimentation, simulations, and electronic recipe management across Operations.
  • Engage with business users to analyze business needs, identify technology solutions, capture and document design, and apply Agile development best practices.
  • Collaborate with Information Systems Architects and System Owners to implement integrated solutions across product lifecycle management, enterprise resource planning, manufacturing execution systems, and the Enterprise Data Lake.
  • Perform hands-on development of technology solutions, including configuration of commercial software and extensions and integrations.
  • Represent the software development team in cross-functional leadership meetings.
  • Serve as lead Solution Engineer and oversee external contractors and consultants.
  • Review project deliverables throughout development for quality, traceability to requirements, and adherence to quality management plans and standards; participate in Information Systems quality validation reviews.
  • Oversee the backlog of requirements and user stories.
  • Collaborate with Platform Owners, Product Owners, Service Owners, and delivery teams to ensure delivery matches commitments, act as a critical issue point, and facilitate communication when service commitments are unmet.
  • Ensure compliance with quality and GxP requirements in technology services, monitor emerging technologies and trends for platform growth, and maintain alignment with strategy, compliance, and regulatory requirements.
Desired Qualifications
  • Solid depth or breadth of expertise with laboratory solution offerings, including electronic laboratory notebooks, inventory management, manufacturing execution systems, and scientific analysis tools.
  • At least 5–8 years of domain knowledge in health and/or life sciences combined with Information Technology.
  • Understanding and applied experience in laboratory informatics and cross-functional data harmonization.
  • Understanding of business, manufacturing, and laboratory systems common in process manufacturing and their integration through applicable standards.
  • Up-to-date knowledge of vendors' software strategies and competing solutions, with the ability to translate them to the changing business environment in Process Development to maximize software investments.
  • Experience managing a globally distributed enterprise application platform.
  • Leadership experience within a highly regulated pharmaceutical or technology organization, including ensuring compliance with industry regulations and standard methodologies for GxP software validation.
  • Experience directing solution design, business process redesign, and software implementation in a drug development laboratory or commercialization environment.
  • Understanding of FDA regulations governing computer system validation and operation in biotech manufacturing and laboratory areas.
  • Strong analytical, critical-thinking, and decision-making abilities.
  • Ability to work effectively in a fast-paced, dynamic environment.
  • Extensive experience in the software development life cycle.
  • Experience using and adopting the Scaled Agile Framework.
  • Understanding of Information Technology Infrastructure Library processes and implementation.
  • Established business partnerships and Information Systems governance practices involving senior business stakeholders.
  • Experience handling vendor relationships and working with external partners or consultants to ensure optimal performance, support, and development of digital products.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • A broad pipeline targets heart disease, obesity, rare disease, inflammation, and cancer.
  • Global reach across roughly 100 countries supports scale and diversification.
  • Legacy cash flows from mature biologics fund new medicine development.

What critics are saying

  • Enbrel faces pricing pressure after Colorado's 70% price-cap challenge.
  • Recent Corlanor and Sensipar recalls expose manufacturing and quality-control weaknesses.
  • Biosimilar competition threatens mature biologics and compresses future margins.

What makes Amgen unique

  • Amgen combines biologics discovery, manufacturing, and commercialization under one integrated platform.
  • Its portfolio spans oncology, cardiovascular, inflammation, bone health, and rare disease.
  • Human genetics and biology guide its drug discovery strategy.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.